Investments
2Partners & Customers
9Service Providers
2About Haemonetics
Haemonetics is a medical device company. It had developed the Haemonetics Cell Saver Elite Autotransfusion System.Haemonetics is a global company that markets automated blood processing systems. These systems help increase the safety, quality and availability of the world blood supply by addressing important medical markets: surgical blood salvage, blood component collections and plasma collections.
Want to inform investors similar to Haemonetics about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Haemonetics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Haemonetics in 2 Expert Collections, including Conference Exhibitors.
Conference Exhibitors
5,302 items
Medical Devices
3,501 items
https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.
Latest Haemonetics News
Mar 14, 2023
The company also announced a €30 million strategic investment from Haemonetics. Sam Brusco, Associate Editor03.13.23 Vivasure Medical, a company pioneering absorbable percutaneous vessel closure technology, has earned a U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) to advance its PATCH clinical study. PATCH is a multi-center, single-arm, pivotal study to evaluate the Vivasure PerQseal closure device system’s safety and effectiveness. The study will enroll up to 188 patients in the U.S. and Europe. Vivasure aims to use the study results to support FDA premarket approval and multinational commercial launch of PerQseal. PerQseal is designed as the first sutureless, fully absorbable synthetic implant for large-bore vessel punctures. A low profile patch can be placed from inside the vessel and aims to make deployment simpler and more controlled than conventional closure techniques, which can result in major vascular complications. Haemonetics Corporation has also invested €30 million in the company as well as part of its Series D financing. The strategic investment includes an option to acquire Vivasure on completion of specific milestones. “We are excited to be moving forward with this multi-center pivotal study which we expect will affirm the safety and effectiveness of PerQseal for large hole arterial closure. Moreover, we are delighted to now be partnered with Haemonetics, which has quickly established itself as a market leader in advanced vessel closure,” Andrew Glass, CEO of Vivasure Medical told the press. “We strongly believe in the potential of our fully absorbable patch-based approach to large hole closure, and these steps mark important progress toward fulfilling our mission of enabling safe and effective advanced structural and percutaneous cardiovascular therapies.” “Vascular closure is a key focus of Haemonetics’ growth strategy, and we are excited about the long-term potential of Vivasure’s innovative technology to advance large hole percutaneous procedures,” said Stew Strong, President, Global Hospital at Haemonetics. Large hole arterial access is needed to perform percutaneous cardiovascular procedures like transcatheter aortic valve replacement (TAVR), thoracic and abdominal endovascular aneurysn repair (TEVAR and EVAR), and use of a cardiac assist device (CAD).
Haemonetics Investments
2 Investments
Haemonetics has made 2 investments. Their latest investment was in Vivasure Medical as part of their Series D - II on March 3, 2023.
Haemonetics Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
3/13/2023 | Series D - II | Vivasure Medical | $34.36M | Yes | 2 | |
12/6/2004 | Series D |
Date | 3/13/2023 | 12/6/2004 |
|---|---|---|
Round | Series D - II | Series D |
Company | Vivasure Medical | |
Amount | $34.36M | |
New? | Yes | |
Co-Investors | ||
Sources | 2 |
Haemonetics Acquisitions
4 Acquisitions
Haemonetics acquired 4 companies. Their latest acquisition was Cardiva Medical on January 20, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
1/20/2021 | Series E+ | $176.72M | Acquired | 5 | ||
4/2/2020 | ||||||
7/18/2006 | Series D | |||||
9/13/2000 | Other Venture Capital |
Date | 1/20/2021 | 4/2/2020 | 7/18/2006 | 9/13/2000 |
|---|---|---|---|---|
Investment Stage | Series E+ | Series D | Other Venture Capital | |
Companies | ||||
Valuation | ||||
Total Funding | $176.72M | |||
Note | Acquired | |||
Sources | 5 |
Haemonetics Partners & Customers
9 Partners and customers
Haemonetics has 9 strategic partners and customers. Haemonetics recently partnered with Epic on August 8, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
8/29/2022 | Client | United States | BOSTON , Aug. 29 , 2022 / PRNewswire / -- Haemonetics Corporation , a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes , today announced an agreement with Epic , a leading Electronic Health Record system , to offer Haemonetics Corporation ' SafeTrace Tx ® blood bank information system to Epic 's global network of hospitals . | 2 | |
12/2/2015 | Partner | ||||
9/30/2015 | Client | ||||
8/20/2015 | Partner | ||||
3/5/2015 | Client |
Date | 8/29/2022 | 12/2/2015 | 9/30/2015 | 8/20/2015 | 3/5/2015 |
|---|---|---|---|---|---|
Type | Client | Partner | Client | Partner | Client |
Business Partner | |||||
Country | United States | ||||
News Snippet | BOSTON , Aug. 29 , 2022 / PRNewswire / -- Haemonetics Corporation , a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes , today announced an agreement with Epic , a leading Electronic Health Record system , to offer Haemonetics Corporation ' SafeTrace Tx ® blood bank information system to Epic 's global network of hospitals . | ||||
Sources | 2 |
Haemonetics Service Providers
2 Service Providers
Haemonetics has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acquired | Counsel | General Counsel | |
Service Provider | ||
|---|---|---|
Associated Rounds | Acquired | |
Provider Type | Counsel | |
Service Type | General Counsel |
Partnership data by VentureSource
Haemonetics Team
25 Team Members
Haemonetics has 25 team members, including current Chief Executive Officer, President, Chris Simon.
Name | Work History | Title | Status |
|---|---|---|---|
Chris Simon | McKinsey & Company, Baxter Healthcare, and U.S. Army | Chief Executive Officer, President | Current |
Name | Chris Simon | ||||
|---|---|---|---|---|---|
Work History | McKinsey & Company, Baxter Healthcare, and U.S. Army | ||||
Title | Chief Executive Officer, President | ||||
Status | Current |
Compare Haemonetics to Competitors
Sight Diagnostics provides affordable and accurate diagnostics in a compact platform designed for use in qualified labs in low volume settings. Its proprietary machine-vision based technology provides the capability to perform multiple tests on a single, easy-to-operate platform.
Spotlab develops an ecosystem of portable devices connected and controlled with a smartphone to acquire medical images. It is a platform to diagnose remotely, and an artificial intelligence and crowdsourcing assistant that automates part of the analysis of the images.
OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, the company aims to understand patients' unique response to therapy and overcome one of the major obstacles in clinical oncology: resistance to therapy. OncoHost's host response profiling platform, PROphet®, analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e. the host) in response to a given cancer therapy. This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. PROphet® also identifies potential drug targets, advancing the development of therapeutic strategies, as well as rationally-based combination therapies. The company was founded in 2017 and is based in Binyamina, Israel.
Truvian Sciences is a healthcare company at the intersection of diagnostics and consumer technology. Its automated benchtop system produces lab-accurate results for a full suite of health tests using a small sample of blood. Powered by patented technologies and intelligent integration, Truvian's system delivers an alternative to off-site labs, providing immediate insights to inform healthcare decisions.
PixCell Medical Technologies is a privately held company developing cell-based diagnostics for the point of care (POC), based on its viscoelastic focusing and microfluidics technology. The company's core technology is comprised of an analyzer and a self-contained disposable cartridge. On May 3, 2021, PixCell Medical Technologies was acquired by Soulbrain. The terms of the transaction were not disclosed.
Accumen is a healthcare transformation company that partners with health systems to set new standards of performance in the clinical lab. Accumen delivers proven results in Clinical Laboratory Operations and Patient Blood Management with solutions that are designed to help clients create healthier labs, healthier hospitals and, ultimately, healthier communities.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.